The world's oldest living lab rat points the way to rejuvenation

Press Releases »

"Sima", a 47 months-old female rat, is being treated with E5, a treatment intended to recreate the circulatory environment of a young mammal; the maximum recorded lifespan for this species is 45.5 months.

An experiment led by Dr. Harold Katcher, one of the discoverers of the first breast cancer gene, is giving humanity hope of fulfilling the dream of undoing aging. While working at Yuvan Research Inc., he discovered which part of the blood of young animals controls the age of the organism, and tested it in eight Sprague Dawley female rats. "Sima" is the last survivor, but the age she has reached allows us to see a path for human rejuvenation. "Cellular aging is a cell non-autonomous process — it doesn't depend on the cell's history, but on its environment", states Dr. Katcher, Chief Scientific Officer of Yuvan, a startup based in California working on rejuvenation treatments.

This experiment is a follow-up to another experiment showing that Yuvan's therapy caused a 54% rejuvenation in male rats according to an epigenetic clock analysis performed by then UCLA professor Dr. Steve Horvath. Afterward, a Belgian non-profit, HEALES, decided to fund two lifespan studies, one using Yuvan's treatment, called "E5", and another one, led by Dr. Rodolfo Goya, professor at La Plata University (Argentina), using young rat plasma. Dr. Goya's experiment achieved moderate life extension. Yuvan's experiment is still ongoing as Sima is alive at 47 months of age.

Also, Sima and the other treated rats showed a grip strength 2.8 times higher than the controls. According to Dr. Goya, "muscular strength indicates prolonged healthspan." Sima is a Rattus norvegicus, a species with a maximum recorded lifespan of 45.5 months. Their average lifespan is 24-36 months. Yuvan's treatment started when the rats were already 24 months old and even so pushed the maximum lifespan of the species with a treated group comprising only 8 rats. 

The E5 production process is patent-pending, and the story of its discovery is captured in Dr. Katcher's book The Illusion of Knowledge. Yuvan is planning trials in other species before testing it in humans — in human terms, Sima is already 126 years old, considering 122.5 years as the human maximum lifespan. "Sima" means "limit/boundary/frontier" in Sanskrit, and by surpassing the lifespan limit of its species, it reminds us that human history is a history of surpassing limits.

Photo - https://mma.prnewswire.com/media/1997395/sima_2.jpg


ข่าวbreast cancer+o:editorวันนี้

30 Years of Empowerment: Thanyarak Foundation Unveils "The Power of Self-Love" Campaign to Help Protect Against Breast Cancer

In today's world where women are constantly balancing multiple roles as executives, caregivers, and family pillars, their own health often takes a backseat. For the past 30 years, the Thanyarak Foundation under the Royal Patronage of Her Royal Highness Princess Srinagarindra has steadfastly supported Thai women in the fight against breast cancer, in line with Her Royal Highness's vision to protect women from this life-threatening disease. As part of its ongoing mission, the Thanyarak Foundation

Cancer remains one of the most pressing h... AXA Strengthens Cancer Awareness and Prevention Efforts in Thailand — Cancer remains one of the most pressing health challenges in Thailand, with over 180...

Bangkok Dusit Medical Services Public Com... BDMS Launches Breast Cancer Screening Campaign to Promote Early Detection and Prevention — Bangkok Dusit Medical Services Public Company Limited (BDMS), a...

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection , securing exclusive commercialization licensing and supply of...

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor...

Mr. Poonsit Wongthawatchai (left), Krungs... Krungsri supports Breast Foundation in screening breast cancer for disadvantaged women for 14th year — Mr. Poonsit Wongthawatchai (left), Krungsri Executi...